Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), eithe...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Fernandez-Rozadilla, C, Cazier, J, Moreno, V, Crous-Bou, M, Guinó, E, Durán, G, Lamas, M, López, R, Candamio, S, Gallardo, E, Paré, L, Baiget, M, Páez, D, López-Fernández, L, Cortejoso, L, García, M, Bujanda, L, González, D, Gonzalo, V, Rodrigo, L, Reñé, J, Jover, R, Brea-Fernández, A, Andreu, M, Bessa, X
פורמט: Journal article
שפה:English
יצא לאור: 2013
_version_ 1826265867846942720
author Fernandez-Rozadilla, C
Cazier, J
Moreno, V
Crous-Bou, M
Guinó, E
Durán, G
Lamas, M
López, R
Candamio, S
Gallardo, E
Paré, L
Baiget, M
Páez, D
López-Fernández, L
Cortejoso, L
García, M
Bujanda, L
González, D
Gonzalo, V
Rodrigo, L
Reñé, J
Jover, R
Brea-Fernández, A
Andreu, M
Bessa, X
author_facet Fernandez-Rozadilla, C
Cazier, J
Moreno, V
Crous-Bou, M
Guinó, E
Durán, G
Lamas, M
López, R
Candamio, S
Gallardo, E
Paré, L
Baiget, M
Páez, D
López-Fernández, L
Cortejoso, L
García, M
Bujanda, L
González, D
Gonzalo, V
Rodrigo, L
Reñé, J
Jover, R
Brea-Fernández, A
Andreu, M
Bessa, X
author_sort Fernandez-Rozadilla, C
collection OXFORD
description The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale. © 2013 Macmillan Publishers Limited. All rights reserved 1470-269X/13.
first_indexed 2024-03-06T20:30:21Z
format Journal article
id oxford-uuid:30d4b76e-aa26-4ee4-8717-2eed8c12cbb3
institution University of Oxford
language English
last_indexed 2024-03-06T20:30:21Z
publishDate 2013
record_format dspace
spelling oxford-uuid:30d4b76e-aa26-4ee4-8717-2eed8c12cbb32022-03-26T13:04:01ZPharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administrationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:30d4b76e-aa26-4ee4-8717-2eed8c12cbb3EnglishSymplectic Elements at Oxford2013Fernandez-Rozadilla, CCazier, JMoreno, VCrous-Bou, MGuinó, EDurán, GLamas, MLópez, RCandamio, SGallardo, EParé, LBaiget, MPáez, DLópez-Fernández, LCortejoso, LGarcía, MBujanda, LGonzález, DGonzalo, VRodrigo, LReñé, JJover, RBrea-Fernández, AAndreu, MBessa, XThe development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale. © 2013 Macmillan Publishers Limited. All rights reserved 1470-269X/13.
spellingShingle Fernandez-Rozadilla, C
Cazier, J
Moreno, V
Crous-Bou, M
Guinó, E
Durán, G
Lamas, M
López, R
Candamio, S
Gallardo, E
Paré, L
Baiget, M
Páez, D
López-Fernández, L
Cortejoso, L
García, M
Bujanda, L
González, D
Gonzalo, V
Rodrigo, L
Reñé, J
Jover, R
Brea-Fernández, A
Andreu, M
Bessa, X
Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
title Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
title_full Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
title_fullStr Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
title_full_unstemmed Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
title_short Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
title_sort pharmacogenomics in colorectal cancer a genome wide association study to predict toxicity after 5 fluorouracil or folfox administration
work_keys_str_mv AT fernandezrozadillac pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT cazierj pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT morenov pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT crousboum pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT guinoe pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT durang pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT lamasm pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT lopezr pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT candamios pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT gallardoe pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT parel pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT baigetm pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT paezd pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT lopezfernandezl pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT cortejosol pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT garciam pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT bujandal pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT gonzalezd pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT gonzalov pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT rodrigol pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT renej pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT joverr pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT breafernandeza pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT andreum pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration
AT bessax pharmacogenomicsincolorectalcanceragenomewideassociationstudytopredicttoxicityafter5fluorouracilorfolfoxadministration